Egfr-Tyrosine Kinase Inhibitor Treatment Beyond Progression in Long-Term Responders to Erlotinib in Advanced Non-Small Cell Lung Cancer: Relevance of Egfr Mutation Status

Mutation Status ◽

Treatment Beyond Progression ◽

Heterogeneity of the EGFR mutation status between the primary tumor and metastatic lymph node and the sensitivity to EGFR tyrosine kinase inhibitor in non-small cell lung cancer

Targeted Oncology ◽

10.1007/s11523-012-0241-x ◽

2012 ◽

Vol 8 (4) ◽

pp. 237-242 ◽

Cited By ~ 20

Author(s):

Katsuhiko Shimizu ◽

Takuro Yukawa ◽

Yuji Hirami ◽

Riki Okita ◽

Shinsuke Saisho ◽

...

Keyword(s):

Lung Cancer ◽

Lymph Node ◽

Primary Tumor ◽

Egfr Mutation ◽

Kinase Inhibitor ◽

Metastatic Lymph Node ◽

Small Cell ◽

Small Cell Lung ◽

Mutation Status

RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation

Lung Cancer ◽

10.1016/j.lungcan.2015.09.025 ◽

2015 ◽

Vol 90 (3) ◽

pp. 477-483 ◽

Cited By ~ 25

Author(s):

Tatsuya Yoshida ◽

Kiyotaka Yoh ◽

Seiji Niho ◽

Shigeki Umemura ◽

Shingo Matsumoto ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cancer Patients ◽

Egfr Mutation ◽

Kinase Inhibitor ◽

Small Cell ◽

Small Cell Lung ◽

Lung Cancer Patients ◽

MA18.05 Characteristics and Long-Term OS of Non-Small Cell Lung Cancer Patients Receiving EGFR Tyrosine Kinase Inhibitor Treatment

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2018.08.468 ◽

2018 ◽

Vol 13 (10) ◽

pp. S419

Author(s):

M. Bergqvist ◽

H. Nordahl Christensen ◽

F. Wiklund ◽

S. Bergström

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cancer Patients ◽

Kinase Inhibitor ◽

Small Cell ◽

Small Cell Lung ◽

Lung Cancer Patients ◽

EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: A case–control study of overall survival

Lung Cancer ◽

10.1016/j.lungcan.2013.02.010 ◽

2013 ◽

Vol 80 (3) ◽

pp. 306-312 ◽

Cited By ~ 26

Author(s):

M. Faehling ◽

R. Eckert ◽

T. Kamp ◽

S. Kuom ◽

U. Griese ◽

...

Keyword(s):

Case Control Study ◽

Kinase Inhibitor ◽

Case Control ◽

Small Cell ◽

Small Cell Lung ◽

Treatment Beyond Progression ◽

Control Study ◽

Circulating plasma microRNAs as potential markers to identify EGFR mutation status and to monitor epidermal growth factor receptor-tyrosine kinase inhibitor treatment in patients with advanced non-small cell lung cancer

Oncotarget ◽

10.18632/oncotarget.17416 ◽

2017 ◽

Vol 8 (28) ◽

pp. 45807-45824 ◽

Cited By ~ 7

Author(s):

Lili Qu ◽

Liangliang Li ◽

Xiaofei Zheng ◽

Hanjiang Fu ◽

Chuanhao Tang ◽

...

Keyword(s):

Lung Cancer ◽

Receptor Tyrosine Kinase ◽

Egfr Mutation ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Mutation Status ◽

Epidermal Growth ◽

EGFR-tyrosine kinase inhibitor treatment in a patient with advanced non-small cell lung cancer and concurrent exon 19 and 21 EGFR mutations: A case report and review of the literature

Oncology Letters ◽

10.3892/ol.2016.4409 ◽

2016 ◽

Vol 11 (5) ◽

pp. 3546-3550 ◽

Cited By ~ 10

Author(s):

YANG YANG ◽

BIAO ZHANG ◽

RUTIAN LI ◽

BAORUI LIU ◽

LIFENG WANG

Keyword(s):

Lung Cancer ◽

Case Report ◽

Kinase Inhibitor ◽

Small Cell ◽

Egfr Mutations ◽

Review Of The Literature ◽

Small Cell Lung ◽

Inhibitor Treatment ◽

Exon 19

Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-19-1126 ◽

2019 ◽

Vol 25 (22) ◽

pp. 6644-6652 ◽

Cited By ~ 18

Author(s):

Jhanelle E. Gray ◽

Isamu Okamoto ◽

Virote Sriuranpong ◽

Johan Vansteenkiste ◽

Fumio Imamura ◽

...

Keyword(s):

Lung Cancer ◽

Egfr Mutation ◽

Kinase Inhibitor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Egfr Mutated ◽

First Line Treatment

Does the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor differ according to the type of EGFR mutation in non-small cell lung cancer?

The Korean Journal of Internal Medicine ◽

10.3904/kjim.2016.190 ◽

2017 ◽

Vol 32 (3) ◽

pp. 422-428 ◽

Cited By ~ 1

Author(s):

Yong Won Choi ◽

Jin-Hyuk Choi

Keyword(s):

Lung Cancer ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Egfr Mutation ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Epidermal Growth

481TiP Checkmate 722: A phase 3 trial of nivolumab with chemotherapy or ipilimumab vs chemotherapy in epidermal growth factor receptor (EGFR)-mutation, T790M-negative stage IV or recurrent non-small cell lung cancer (NSCLC) after EGFR tyrosine kinase inhibitor (TKI) therapy

Annals of Oncology ◽

10.1093/annonc/mdw594.045 ◽

2016 ◽

Vol 27 (suppl_9) ◽

Cited By ~ 2

Author(s):

K. Nakagawa ◽

J.C-H. Yang ◽

K. Park ◽

Y. Ohe ◽

Y-L. Wu ◽

...

Keyword(s):

Lung Cancer ◽

Egfr Mutation ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Stage Iv ◽

Small Cell ◽

Small Cell Lung ◽

Phase 3 ◽

Epidermal Growth

Treatment and prognosis after progression in long-term responders to EGFR-tyrosine kinase inhibitor in advanced non-small cell lung cancer

Archives of Medical Science ◽

10.5114/aoms.2016.57586 ◽

2016 ◽

Vol 1 ◽

pp. 107-111 ◽

Cited By ~ 2

Author(s):

Zhengbo Song ◽

Yiping Zhang

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Tyrosine Kinase Inhibitor ◽

Cell Lung Cancer ◽

Kinase Inhibitor ◽

Small Cell ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor